Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

Background: Patients with immunocompromised disorders have mainly been excluded from clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial was to investigate safety and efficacy of BNT162b2 mRNA vaccination in five selected groups of immunocompromised pati...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Peter Bergman, MD, Ola Blennow, MD, Lotta Hansson, MD, Stephan Mielke, MD, Piotr Nowak, MD, Puran Chen, MD, Gunnar Söderdahl, MD, Anders Österborg, MD, C. I. Edvard Smith, MD, David Wullimann, MSc, Jan Vesterbacka, MD, Gustaf Lindgren, MD, Lisa Blixt, MD, Gustav Friman, MD, Emilie Wahren-Borgström, MD, Anna Nordlander, MD, Angelica Cuapio Gomez, MD, Mira Akber, MD, Davide Valentini, MD, Anna-Carin Norlin, MD, Anders Thalme, MD, Gordana Bogdanovic, MD, Sandra Muschiol, MD, Peter Nilsson, MD, Sophia Hober, MD, Karin Loré, MD, Margaret Sällberg Chen, MD, Marcus Buggert, MD, Hans-Gustaf Ljunggren, MD, Per Ljungman, MD, Soo Aleman, MD
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
mRNA BNT162b2 vaccine
Immunocompromised patients
Primary Immunodeficiency
HIV
human stem-cell transplantation
CAR-T
Medicine
R
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/4718ffd4f65749848e9d9b7f48c73d1b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/4718ffd4f65749848e9d9b7f48c73d1b

Ejemplares similares